IGBA applauds long-awaited scientific harmonization process of bioequivalence studies (December 2019)The International Generic and Biosimilar Medicines Association (IGBA) welcomes the adoption by the International Council for Harmonization (ICH) of a new topic proposal on Bioequivalence for ImmediateRelease Solid Oral Dosage Forms (M13)i . The ICH Assembly approved the Concept Paper Outline… Read More
IGBA Statement on Hosting of Pat-INFORMED by WIPO (December 2019)Since September 2018 the World Intellectual Property Organization (WIPO) has hosted the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) patent database Pat-INFORMEDi on its website. This database is simply a posting of unverified patent information provided directly by originator… Read More
WHO signs MoU with International Generic and Biosimilar Medicines Association to promote access (October 2019)Full access to medicines is hampered by a variety of factors. Two important barriers are high prices and regulatory issues such as long lag times in bringing medicines to market. Read More
IGBA recommendations for action to support a sustainable global pharmaceutical market for continued patient access worldwide to safe, effective and high-quality medicines (October 2019)IGBA recommendations for action to support a sustainable global pharmaceutical market for continued patient access worldwide to safe, effective and high-quality medicines (October 2019) Read More
Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.
In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.
The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. To reflect the evolving nature of the industry, in late 2015, IGPA incorporated under Swiss Law, and at the same time changed the name of the organization to the International Generic and Biosimilar Medicines Association (IGBA).